Plasmid Engineering

Start strong by designing the right plasmid backbone for your gene editing system. Our SnapFast® catalog and custom plasmid engineering services help ensure high transgene expression, yield, and control — from CRISPR payloads to viral vector packaging. With proven expertise in complex genes of interest, we can boost vector yields by up to 3-fold through advanced plasmid optimization.

Cell Banking

Establish robust, regulatory-ready master (MCB) and working cell banks (WCB) (e.g. for MSC). Our global facilities support GMP-compliant cell banking with full characterization, documentation, and integrated release testing.

Viral Vector Services

Access scalable AAV and LVV manufacturing solutions built for gene-modified cell therapy. From plasmid supply to final fill, we support seamless vector production under GMP.

Cell Therapy Services

Minaris provides comprehensive end-to-end CDMO support for allogeneic therapies, encompassing process development, GMP manufacturing and global distribution. Our extensive experience with allogeneic CAR-T, CAR-NK, TCR-T, HSC, MSC, and iPSC-derived immune cells ensures program success. We routinely use off-the-shelf as well as proprietary manufacturing platforms that allow scalability, efficiency and cost reduction, such as 3D suspension and adherent bioreactor-based platforms.

During process development (PD) we assess the suitability of current platforms and provide scale-up or scale-out solutions for your allogeneic Cell Therapy. During this phase we also evaluate all raw materials for GMP use and provide a comprehensive data package for your CMC submissions.

Testing Services

Robust, scalable and timely in-process and release testing is a critical element of allogeneic Cell Therapy. Through our extensive in-house testing capabilities, we streamline processes so patients receive the therapy safely and quickly. We offer biosafety, identity, potency, stability, and release assays co-located and integrated with manufacturing.

During analytical development (AD) and tech transfer, we evaluate all assays to be scientifically sound and fit-for-purpose. State-of-the-art equipment is used for in-process control testing as well as future release testing. Surrogate assays for potency assessment and potency assurance programs can be developed concurrently. In-use stability or on/off target sequencing analysis needed? No problem! Speak with our analytical experts to learn more about our experience and ever-increasing offerings. We can even provide a comprehensive data package for your CMC submission.